Article Type
Changed
Wed, 12/14/2016 - 10:29
Display Headline
DEVELOPING STORY: Abbott Agrees to Pull Obesity Drug Meridia Off the Market

The Food and Drug Administration announced today that Meridia (sibutramine), a drug used for treating obesity, will be voluntarily removed from the U.S. market by its maker, Abbott Laboratories. The withdrawal is the result of clinical trial data indicating an association between Meridia use and increased risk of heart attack and stroke.

Author and Disclosure Information

Publications
Topics
Author and Disclosure Information

Author and Disclosure Information

The Food and Drug Administration announced today that Meridia (sibutramine), a drug used for treating obesity, will be voluntarily removed from the U.S. market by its maker, Abbott Laboratories. The withdrawal is the result of clinical trial data indicating an association between Meridia use and increased risk of heart attack and stroke.

The Food and Drug Administration announced today that Meridia (sibutramine), a drug used for treating obesity, will be voluntarily removed from the U.S. market by its maker, Abbott Laboratories. The withdrawal is the result of clinical trial data indicating an association between Meridia use and increased risk of heart attack and stroke.

Publications
Publications
Topics
Article Type
Display Headline
DEVELOPING STORY: Abbott Agrees to Pull Obesity Drug Meridia Off the Market
Display Headline
DEVELOPING STORY: Abbott Agrees to Pull Obesity Drug Meridia Off the Market
Article Source

PURLs Copyright

Inside the Article